Related Experiment Video
Updated: May 29, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
Soon Sun Kim1, Jae Youn Cheong, Sung Won Cho
1Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Abstract:
Although the prevalence of chronic hepatitis B has decreased considerably in recent years due to widespread use of the hepatitis B virus (HBV) vaccine, its prevalence still remains high in adults, and this can place a significant burden on health care in areas with endemic HBV. Since the introduction of nucleos(t)ide analogues (NUCs), there has been marked improvement in the care of patients with chronic hepatitis B, resulting in increased survival. However, the emergence of drug resistance in patients treated with NUCs is a major concern. The number of multi-drug resistant patients is increasing, and many patients may not respond to the currently available drugs. In this review, we describe the current status of NUC therapy for antiviral-naïve and -resistant patients.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Viruses with RNA Genomes
Retrovirus Life Cycles

